Zain Ul Abedeen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zain Ul Abedeen has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Zia Ullah
Department of medicine, Saidu Medical College, Swat, Pakistan
11 shared publications - Abad Ur Rehman
Department of Medicine Spinghar University (Kabul Campus) Kabul Afghanistan
8 shared publications - Ayesha Saleem
Saidu Medical College, Swat, Pakistan
5 shared publications - Abdur Rehman
Department of medicine, Saidu Medical College, Swat, Pakistan
3 shared publications Muhammad Zaib
Saidu Medical College, Swat, Pakistan
3 shared publications- Muhammad Zeeshan Ghani
Services Institute of Medical Sciences Lahore Pakistan
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11)
Acute Hematemesis Leading to the Incidental Diagnosis of Esophageal Squamous Cell Carcinoma in an Adolescent: First Case Report From Pakistan
Esophageal squamous cell carcinoma (ESCC) is exceptionally rare in children and adolescents and typically presents with progressive dysphagia and weight loss. Its occurrence without conventional risk factors may pose a diagnostic challenge. A 16‐year‐old boy presented with acute hematemesis and no history of dysphagia, odynophagia, or recognized esophageal cancer risk factors. He was undernourished, with a BMI of 17 kg/m 2 and progressive unquantified weight loss. Upper gastrointestinal endoscopy revealed a deep proximal esophageal ulcer, distal esophageal ulcers, a Mallory‐Weiss tear, and gastritis. The latter lesions offered potential explanations for the bleeding, but the atypical proximal ulcer raised suspicion for malignancy, prompting biopsy. Histopathology confirmed moderately differentiated ESCC with high‐grade dysplasia. Contrast‐enhanced CT showed localized upper thoracic esophageal wall thickening without regional lymphadenopathy or distant metastases, and the disease was staged as T2N0M0. The patient completed three cycles of neoadjuvant carboplatin‐paclitaxel‐based chemotherapy followed by radiotherapy. A repeat endoscopy showed a circumferential raw mucosal area with a superficial erosion in the distal esophagus, while the upper and middle thirds of the esophagus appeared normal; however, esophagectomy was recommended as part of the planned definitive management. This case highlights the incidental discovery of ESCC during evaluation of acute hematemesis in an adolescent without conventional risk factors. Hematemesis with low BMI or unexplained weight loss should prompt careful evaluation for underlying esophageal pathology, even when an apparent benign bleeding source is identified. Early biopsy, appropriate staging, and multidisciplinary management are essential for timely diagnosis and treatment.
- 10 November 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (11)
Open AccessAcute Hematemesis Leading to the Incidental Diagnosis of Esophageal Squamous Cell Carcinoma in an Adolescent: First Case Report From Pakistan
Esophageal squamous cell carcinoma (ESCC) is exceptionally rare in children and adolescents and typically presents with progressive dysphagia and weight loss. Its occurrence without conventional risk factors may pose a diagnostic challenge. A 16‐year‐old boy presented with acute hematemesis and no history of dysphagia, odynophagia, or recognized esophageal cancer risk factors. He was undernourished, with a BMI of 17 kg/m 2 and progressive unquantified weight loss. Upper gastrointestinal endoscopy revealed a deep proximal esophageal ulcer, distal esophageal ulcers, a Mallory‐Weiss tear, and gastritis. The latter lesions offered potential explanations for the bleeding, but the atypical proximal ulcer raised suspicion for malignancy, prompting biopsy. Histopathology confirmed moderately differentiated ESCC with high‐grade dysplasia. Contrast‐enhanced CT showed localized upper thoracic esophageal wall thickening without regional lymphadenopathy or distant metastases, and the disease was staged as T2N0M0. The patient completed three cycles of neoadjuvant carboplatin‐paclitaxel‐based chemotherapy followed by radiotherapy. A repeat endoscopy showed a circumferential raw mucosal area with a superficial erosion in the distal esophagus, while the upper and middle thirds of the esophagus appeared normal; however, esophagectomy was recommended as part of the planned definitive management. This case highlights the incidental discovery of ESCC during evaluation of acute hematemesis in an adolescent without conventional risk factors. Hematemesis with low BMI or unexplained weight loss should prompt careful evaluation for underlying esophageal pathology, even when an apparent benign bleeding source is identified. Early biopsy, appropriate staging, and multidisciplinary management are essential for timely diagnosis and treatment.
- Open Access
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (11) , 7388-7398
Advances in the prevention and management of postoperative nausea and vomiting: a narrative review of pharmacological and integrative approaches
Postoperative nausea and vomiting (PONV) remain a major complication following surgery. Despite the availability of numerous therapies and international guidelines, it affects approximately 25–30% of patients, with rates reaching 80% among high-risk patients. There are currently no effective measures to completely eliminate the risk of PONV partly because of varying guidelines, the high cost of preventive approaches, and inconsistencies in their use across different clinical settings. Therefore, this narrative review aimed to synthesize the most up-to-date evidence on the prevention and management of PONV. A literature review was performed using MEDLINE and Google Scholar from January 2020 to July 2025 and included meta-analyses, RCTs, and systematic and narrative reviews published after the 2020 guidelines on the management of PONV. Current evidence supports an individualized and multimodal approach to the prevention of PONV, based on artificial intelligence (AI)-assisted risk stratification using the Apfel and Koivuranta scores. In addition, evidence from the literature includes several new pharmacological agents that can be used as adjuncts to established therapies. These include NK-1 antagonists, long-acting 5-HT3 antagonists, and repurposed medications such as midazolam, olanzapine, mirtazapine, and pyridoxine. Evidence regarding integrative approaches, including acustimulation, acupuncture, music, and gum therapy, is promising and appears to be cost-effective. Therefore, the use of individualized multimodal PONV management that combines pharmacological and non-pharmacological strategies will improve the overall prevention of PONV and patient satisfaction. There is a need for further studies of the relationship between pharmacogenomics, AI-assisted risk prediction, and the cost-effectiveness of PONV management in various health care settings.
- 14 October 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (11) , 7388-7398
Open AccessAdvances in the prevention and management of postoperative nausea and vomiting: a narrative review of pharmacological and integrative approaches
Postoperative nausea and vomiting (PONV) remain a major complication following surgery. Despite the availability of numerous therapies and international guidelines, it affects approximately 25–30% of patients, with rates reaching 80% among high-risk patients. There are currently no effective measures to completely eliminate the risk of PONV partly because of varying guidelines, the high cost of preventive approaches, and inconsistencies in their use across different clinical settings. Therefore, this narrative review aimed to synthesize the most up-to-date evidence on the prevention and management of PONV. A literature review was performed using MEDLINE and Google Scholar from January 2020 to July 2025 and included meta-analyses, RCTs, and systematic and narrative reviews published after the 2020 guidelines on the management of PONV. Current evidence supports an individualized and multimodal approach to the prevention of PONV, based on artificial intelligence (AI)-assisted risk stratification using the Apfel and Koivuranta scores. In addition, evidence from the literature includes several new pharmacological agents that can be used as adjuncts to established therapies. These include NK-1 antagonists, long-acting 5-HT3 antagonists, and repurposed medications such as midazolam, olanzapine, mirtazapine, and pyridoxine. Evidence regarding integrative approaches, including acustimulation, acupuncture, music, and gum therapy, is promising and appears to be cost-effective. Therefore, the use of individualized multimodal PONV management that combines pharmacological and non-pharmacological strategies will improve the overall prevention of PONV and patient satisfaction. There is a need for further studies of the relationship between pharmacogenomics, AI-assisted risk prediction, and the cost-effectiveness of PONV management in various health care settings.
- Open Access
- 11 October 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (10) , e71227
OX40 – OX40L Structural Insights Applied to Rocatinlimab in Atopic Dermatitis With Alopecia Areata Overlap: Mechanistic Hypotheses and Hair Regrowth
- 11 October 2026
- Published by Wiley in Journal of Cosmetic Dermatology
- Vol. 25 (10) , e71227
Open AccessOX40 – OX40L Structural Insights Applied to Rocatinlimab in Atopic Dermatitis With Alopecia Areata Overlap: Mechanistic Hypotheses and Hair Regrowth
- Open Access
- 22 September 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 163
Transcranial magnetic stimulation in autism spectrum disorder: a narrative review of neurobiological mechanisms, clinical efficacy, and future directions
Background: Autism Spectrum Disorder (ASD) is a complicated neuropsychological disorder associated with social communicational problems, stereotypical interests, and behavior patterns. Though ASD has many causes, there are no treatment modalities today that have an overall impact on the condition itself, leaving room for improvement in existing approaches. Transcranial Magnetic Stimulation (TMS) is one of the innovative approaches to treat such disorders by means of a noninvasive method of neuron activation using a strong magnetic field. Body: The TMS could have an influence on the interconnection of the brain networks, synaptic plasticity, and the brain cortex excitability, which are associated with the alleviation of the symptoms of ASD. Although some randomized and open-label studies have reported improvement, the evidence is weakened by small samples, inconsistent protocols, and the large proportion of uncontrolled studies. This would mean that the process of selecting patients as well as administering TMS would need careful attention. There are no documented long-term impacts of TMS. For future studies, there should be incorporation of the principles from neuroimaging and electrophysiology. TMS is performed using different techniques depending on its objectives, which include single-pulse TMS that assesses brain topography; paired-pulse TMS in evaluating the inhibitory or facilitating nature of the brain cortex; repetitive TMS (rTMS). Conclusion: It can be concluded from all the information presented above that TMS might have immense potential as an add-on treatment for ASDs based on the data we have accumulated. However, more studies are needed to assess the efficacy of this treatment method in addressing ASDs.To summarize, TMS is a relatively novel neuromodulation therapy that can benefit individuals with ASDs based on the neurobiological aspects of their disorders.
- 22 September 2026
- Published by Springer Nature in Egyptian Journal of Neurosurgery
- Vol. 41 (1) , 163
Open AccessTranscranial magnetic stimulation in autism spectrum disorder: a narrative review of neurobiological mechanisms, clinical efficacy, and future directions
Background: Autism Spectrum Disorder (ASD) is a complicated neuropsychological disorder associated with social communicational problems, stereotypical interests, and behavior patterns. Though ASD has many causes, there are no treatment modalities today that have an overall impact on the condition itself, leaving room for improvement in existing approaches. Transcranial Magnetic Stimulation (TMS) is one of the innovative approaches to treat such disorders by means of a noninvasive method of neuron activation using a strong magnetic field. Body: The TMS could have an influence on the interconnection of the brain networks, synaptic plasticity, and the brain cortex excitability, which are associated with the alleviation of the symptoms of ASD. Although some randomized and open-label studies have reported improvement, the evidence is weakened by small samples, inconsistent protocols, and the large proportion of uncontrolled studies. This would mean that the process of selecting patients as well as administering TMS would need careful attention. There are no documented long-term impacts of TMS. For future studies, there should be incorporation of the principles from neuroimaging and electrophysiology. TMS is performed using different techniques depending on its objectives, which include single-pulse TMS that assesses brain topography; paired-pulse TMS in evaluating the inhibitory or facilitating nature of the brain cortex; repetitive TMS (rTMS). Conclusion: It can be concluded from all the information presented above that TMS might have immense potential as an add-on treatment for ASDs based on the data we have accumulated. However, more studies are needed to assess the efficacy of this treatment method in addressing ASDs.To summarize, TMS is a relatively novel neuromodulation therapy that can benefit individuals with ASDs based on the neurobiological aspects of their disorders.
- Open Access
- 21 September 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (5) , e70464
Catheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Reduced or Mildly Reduced Ejection Fraction: A GRADE ‐Assessed Systematic Review and Meta‐Analysis
Background: Catheter ablation is an established rhythm‐control strategy for atrial fibrillation (AF), but its effectiveness in patients with heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF) remains incompletely defined. We performed a GRADE‐assessed systematic review and meta‐analysis comparing catheter ablation with conventional medical therapy in this population. Methods: PubMed, Embase, and the Cochrane Library were searched from inception to February 2026. Randomized controlled trials and observational cohort studies enrolling adults with AF and left ventricular ejection fraction (LVEF) ≤ 50% were included. Primary outcomes were all‐cause mortality, cardiovascular mortality, and change in LVEF. Secondary outcomes were change in B‐type natriuretic peptide (BNP) and cardiovascular hospitalization. Random‐effects models were used, and certainty of evidence was assessed using GRADE. Results: Thirteen studies involving 131 492 participants were included. Catheter ablation significantly reduced all‐cause mortality (RR 0.61, 95% CI 0.51–0.71) and cardiovascular mortality (RR 0.46, 95% CI 0.31–0.66), improved LVEF (MD 6.47%, 95% CI 4.47–8.47), and reduced BNP levels (MD −136.85 pg/mL, 95% CI −190.46 to −83.23). No significant reduction was observed in cardiovascular hospitalization (RR 0.78, 95% CI 0.53–1.13). Mortality benefits were consistent across subgroup analyses by study design and baseline LVEF. Conclusions: Catheter ablation was associated with lower mortality and improved cardiac function compared with medical therapy in patients with AF and HFrEF/HFmrEF. Further studies specifically evaluating HFmrEF populations are warranted.
- 21 September 2026
- Published by Wiley in Journal of Arrhythmia
- Vol. 42 (5) , e70464
Open AccessCatheter Ablation Versus Medical Therapy in Atrial Fibrillation With Heart Failure With Reduced or Mildly Reduced Ejection Fraction: A GRADE ‐Assessed Systematic Review and Meta‐Analysis
Background: Catheter ablation is an established rhythm‐control strategy for atrial fibrillation (AF), but its effectiveness in patients with heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF) remains incompletely defined. We performed a GRADE‐assessed systematic review and meta‐analysis comparing catheter ablation with conventional medical therapy in this population. Methods: PubMed, Embase, and the Cochrane Library were searched from inception to February 2026. Randomized controlled trials and observational cohort studies enrolling adults with AF and left ventricular ejection fraction (LVEF) ≤ 50% were included. Primary outcomes were all‐cause mortality, cardiovascular mortality, and change in LVEF. Secondary outcomes were change in B‐type natriuretic peptide (BNP) and cardiovascular hospitalization. Random‐effects models were used, and certainty of evidence was assessed using GRADE. Results: Thirteen studies involving 131 492 participants were included. Catheter ablation significantly reduced all‐cause mortality (RR 0.61, 95% CI 0.51–0.71) and cardiovascular mortality (RR 0.46, 95% CI 0.31–0.66), improved LVEF (MD 6.47%, 95% CI 4.47–8.47), and reduced BNP levels (MD −136.85 pg/mL, 95% CI −190.46 to −83.23). No significant reduction was observed in cardiovascular hospitalization (RR 0.78, 95% CI 0.53–1.13). Mortality benefits were consistent across subgroup analyses by study design and baseline LVEF. Conclusions: Catheter ablation was associated with lower mortality and improved cardiac function compared with medical therapy in patients with AF and HFrEF/HFmrEF. Further studies specifically evaluating HFmrEF populations are warranted.
- Open Access
- 14 August 2026
- Published by Wiley in Portal Hypertension & Cirrhosis
Re‐Evaluating the Comparison of Four Different Ultrasound Elastography Techniques for Diagnosing Advanced Fibrosis
- 14 August 2026
- Published by Wiley in Portal Hypertension & Cirrhosis
Open AccessRe‐Evaluating the Comparison of Four Different Ultrasound Elastography Techniques for Diagnosing Advanced Fibrosis
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50088
Mixed phenotype acute leukemia mimicking adult-onset Still’s disease in a pregnant female: A rare case report
Introduction: Mixed phenotype acute leukemia (MPAL) is an uncommon hematologic malignancy characterized by the coexistence of lymphoid and myeloid lineage markers. Although adult-onset Still’s disease (AOSD) is a diagnosis of exclusion, MPAL may rarely present with similar laboratory and clinical findings, resulting in delayed diagnosis and treatment. Case presentation: We report a case of a 36-year-old woman who presented at 20 weeks of gestation with inflammatory polyarthritis, hyperferritinemia, lymphadenopathy, thrombocytopenia, and leukocytosis. The patient fulfilled the Yamaguchi criteria for AOSD after exclusion of autoimmune and infectious conditions and was initially treated with hydroxychloroquine and corticosteroids. An inefficient response to treatment and persistent cytopenias led to reevaluation. A repeat peripheral smear revealed blast cells, and flow cytometry confirmed MPAL. Gestation-compatible chemotherapy protocols resulted in a favorable clinical and hematologic response, with no adverse maternal or fetal outcomes. Clinical discussion: The clinical overlap between the manifestations of AOSD and MPAL may occasionally result in misdiagnosis and delayed detection of an underlying malignancy. In patients presenting with presumed AOSD, careful exclusion of hematologic cancers is essential, particularly in the presence of atypical features such as persistent systemic inflammation, cytopenias, or poor therapeutic response. Conclusion: This case describes a rare association between the manifestations of AOSD and MPAL. In addition, it highlights the importance of recognizing warning signs that may indicate an underlying malignancy in patients presenting with AOSD-like symptoms.
- 7 August 2026
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (32) , e50088
Open AccessMixed phenotype acute leukemia mimicking adult-onset Still’s disease in a pregnant female: A rare case report
Introduction: Mixed phenotype acute leukemia (MPAL) is an uncommon hematologic malignancy characterized by the coexistence of lymphoid and myeloid lineage markers. Although adult-onset Still’s disease (AOSD) is a diagnosis of exclusion, MPAL may rarely present with similar laboratory and clinical findings, resulting in delayed diagnosis and treatment. Case presentation: We report a case of a 36-year-old woman who presented at 20 weeks of gestation with inflammatory polyarthritis, hyperferritinemia, lymphadenopathy, thrombocytopenia, and leukocytosis. The patient fulfilled the Yamaguchi criteria for AOSD after exclusion of autoimmune and infectious conditions and was initially treated with hydroxychloroquine and corticosteroids. An inefficient response to treatment and persistent cytopenias led to reevaluation. A repeat peripheral smear revealed blast cells, and flow cytometry confirmed MPAL. Gestation-compatible chemotherapy protocols resulted in a favorable clinical and hematologic response, with no adverse maternal or fetal outcomes. Clinical discussion: The clinical overlap between the manifestations of AOSD and MPAL may occasionally result in misdiagnosis and delayed detection of an underlying malignancy. In patients presenting with presumed AOSD, careful exclusion of hematologic cancers is essential, particularly in the presence of atypical features such as persistent systemic inflammation, cytopenias, or poor therapeutic response. Conclusion: This case describes a rare association between the manifestations of AOSD and MPAL. In addition, it highlights the importance of recognizing warning signs that may indicate an underlying malignancy in patients presenting with AOSD-like symptoms.
- Open Access
- 18 June 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72981
Bilateral Brucellar Sacroiliitis Mimicking Tuberculous or Inflammatory Spondyloarthropathy: A Case Report
Brucellosis is a zoonotic infection, endemic in rural areas. It is caused by Brucella species, which are transmitted through the intake of unpasteurized dairy products and contact with infected animals. Sacroiliac joint involvement is common in brucellosis and typically presents as unilateral sacroiliitis. Contrarily, bilateral sacroiliitis is less typical and may mimic tuberculosis, pyogenic infection, or inflammatory spondyloarthropathy. We report a case of a 19‐year‐old man who presented with a one‐month history of bilateral buttock pain radiating to the legs and a 2‐week history of fever, chills, rigors, and febrile diaphoresis. He reported unpasteurized milk intake. Physical examination revealed bilateral sacroiliac joint tenderness, and Patrick's and Gaenslen's provocation tests elicited pain in both sacroiliac joints. Laboratory findings showed leukocytosis, elevated CRP, and ESR. Standard agglutination testing was positive for anti‐Brucella antibodies, and MRI confirmed bilateral sacroiliitis, along with erosive changes and marrow edema. A diagnosis of brucellosis complicated by bilateral sacroiliitis was proposed. The patient was started on doxycycline, co‐trimoxazole, and gentamicin. Gentamicin was used for 22 days, while doxycycline and co‐trimoxazole were continued for a total planned duration of 13 weeks. During follow‐up visits (day 15 and day 45), the patient demonstrated clinical improvement, evident by laboratory parameters, pain improvement, no fever, difficulty walking, and medication‐related adverse effects. This case emphasizes that clinicians in endemic areas must consider brucellosis as a differential diagnosis in patients with bilateral lower back or buttock pain. MRI findings and serology testing are useful in early recognition. While blood cultures, PCR, and biopsy are necessary for definitive diagnosis.
- 18 June 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (6) , e72981
Open AccessBilateral Brucellar Sacroiliitis Mimicking Tuberculous or Inflammatory Spondyloarthropathy: A Case Report
Brucellosis is a zoonotic infection, endemic in rural areas. It is caused by Brucella species, which are transmitted through the intake of unpasteurized dairy products and contact with infected animals. Sacroiliac joint involvement is common in brucellosis and typically presents as unilateral sacroiliitis. Contrarily, bilateral sacroiliitis is less typical and may mimic tuberculosis, pyogenic infection, or inflammatory spondyloarthropathy. We report a case of a 19‐year‐old man who presented with a one‐month history of bilateral buttock pain radiating to the legs and a 2‐week history of fever, chills, rigors, and febrile diaphoresis. He reported unpasteurized milk intake. Physical examination revealed bilateral sacroiliac joint tenderness, and Patrick's and Gaenslen's provocation tests elicited pain in both sacroiliac joints. Laboratory findings showed leukocytosis, elevated CRP, and ESR. Standard agglutination testing was positive for anti‐Brucella antibodies, and MRI confirmed bilateral sacroiliitis, along with erosive changes and marrow edema. A diagnosis of brucellosis complicated by bilateral sacroiliitis was proposed. The patient was started on doxycycline, co‐trimoxazole, and gentamicin. Gentamicin was used for 22 days, while doxycycline and co‐trimoxazole were continued for a total planned duration of 13 weeks. During follow‐up visits (day 15 and day 45), the patient demonstrated clinical improvement, evident by laboratory parameters, pain improvement, no fever, difficulty walking, and medication‐related adverse effects. This case emphasizes that clinicians in endemic areas must consider brucellosis as a differential diagnosis in patients with bilateral lower back or buttock pain. MRI findings and serology testing are useful in early recognition. While blood cultures, PCR, and biopsy are necessary for definitive diagnosis.
- 29 May 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (7) , 2218-2219
Re‐Evaluating the J‐GESS Score : A 5‐Year Unified Risk Prediction Model for Gastric Cancer and Esophageal Squamous Cell Carcinoma
- 29 May 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (7) , 2218-2219
Re‐Evaluating the J‐GESS Score : A 5‐Year Unified Risk Prediction Model for Gastric Cancer and Esophageal Squamous Cell Carcinoma